Treating patients like individuals

About iDose

iDose provides the means for rapid, effective titration and optimal pharmacologic intervention

The iDose software is a new web-based software application specifically developed to facilitate dosing of drug agents by integrating real patient’s clinical characteristics into Bayesian model based algorithms.

The software uses clinical observations and patient laboratory measurements, and the physician selects a subjective marker, e.g. drug trough level, that is related to the dose of the drug.  Based on these inputs, the Baysient software calculates and provides the physician with multiple dosing regimens that could allow the patient to maintain the specified drug trough level.  By taking a second measurement of the marker, the physician can assess the accuracy of the prediction by comparing the two values.

The database necessary for the iDose software includes all available information about the subject drug as well as a surrogate marker of response (e.g. concentration) and patient findings.  Statistical modeling is then applied with numerical values based on the following parameters: subject’s last dose, surrogate marker response, current dose and the desired surrogate marker response.  Other inputs may include demographic and laboratory information, concomitant medications, drug level, and dosing information (amount and interval).

The software provides a standardized, auditable and measurable means to optimize dose calculations.  The technique provides the means for rapid, effective titration and optimal pharmacologic intervention.  The accuracy of the prediction can be independently assessed by physician by taking another measurement of the marker which should agree with the initial target value set by the physician.


Try the demo for free

The team

Diane Mould

Dr Mould obtained her bachelors degree at Stevens Institute of Technology in 1984 in Chemistry and Chemical Biology. She received her PhD in Pharmaceutics and Pharmaceutical Chemistry at The Ohio State University (OSU) in 1989. She spent 26 years as a pharmacokineticist in industry where she specialized in population pharmacokinetic / pharmacodynamic modeling and was an associate Research Professor at Georgetown University. She has conducted population PK/PD analyses of hematopoietic agents, monoclonal antibodies, anti-cancer and anti-viral agents, antipsychotic, cardiovascular, and sedative/hypnotic agents. Dr Mould is involved in clinical trial simulation and optimal study design in drug development. She was a member of the Scientific Advisory Group for PharSight, where she assisted in development of clinical trial simulation software.

Currently, Dr Mould is president of Projections Research Inc., a consulting company offering pharmacokinetic and pharmacometric services. She is also the founder of Baysient LLC, a company that develops systems to individualize doses of drugs that are difficult to manage.  

She has published 77 peer-reviewed articles, 17 book chapters, made 106 national and international presentations and presented 6 podium sessions on advanced modeling and simulation approaches.  Dr Mould has authored 101 posters at both national and international meetings. She is an adjunct professor at the University of Rhode Island (URI), OSU, and the University of Florida, and teaches an annual class on disease progression modeling at the National Institutes of Health.  Dr Mould taught 9 courses (OSU, URI and SUNY Buffalo) on specialized aspects of population pharmacokinetic and dynamic modeling.  She is a member of the editorial board for Journal of Pharmacokinetics and Pharmacodynamics, Clinical Pharmacology and Therapeutics, and Clinical Pharmacology and Therapeutics Pharmacometrics and Systems Pharmacology. Dr. Mould is a member of the Board of Regents for the American College of Clinical Pharmacology and is chairman of the Publications committee for this organization.  She is a Fellow of the American College of Clinical Pharmacology and of the American Association of Pharmaceutical Sciences.

Professional Organizations:

AAPS, ACCP, ASCPT, ASoP, DIA, New York Academy of Sciences

List of publications

Cliff Grant

Cliff has worked in bio-medical research since 1984 in fields ranging from hypertension, respiration physiology, cerebral hypoxia to the pharmacokinetics of analgesics and anaesthetics. His M. Med. Sc from the University of Adelaide investigated the role of alpha-2 agonists for the treatment of common painful husbandry procedures in sheep.

Recent work has focused on patient safety during the peri-operative process. From examining intra-operative adverse events to developing and validating a computer led process for patient health assessment and decision making prior to surgery. This work was acknowledged with a Best Scientific Paper for 2012 award from the journal Anaesthesia and Intensive Care. The software and assessment model developed by Cliff have been trialled in 4 major teaching hospitals within Australia and are currently being migrated in to the existing patient pre-operative process for ongoing implementation in at least one of these. hospitals.

Cliff has authored and co-authored over 70 peer-reviewed publications.

Richard Upton

Richard has a BSc degree in general biology from Flinders University. He completed a PhD in 1989 at the Flinders Medical Centre, South Australia under the supervision of Professors Laurie Mather and Bill Runciman. His thesis investigated the physiological basis of drug disposition in specific organs and regions of the body using a chronically instrumented sheep preparation.

From 1989 to 2009 at the Royal Adelaide Hospital, Dr Upton continued this large animal work investigating the physiological mechanisms underlying the absorption, distribution, metabolism and elimination of a number of drugs used in anaesthesia. Dr Upton also developed physiologically based pharmacokinetic-pharmacodynamic models to analyse data from this laboratory. He has contributed to pre-clinical drug development, including modelling and scaling of animal data to predict first dose in man. Clinical studies have included conducting Phase I and other clinical trials, and particularly the population pharmacokinetic analysis of data from clinical trials using NONMEM and other software.

Dr Upton has published over 130 papers and supervised a number of postgraduate students and post-docs.

John James

John read Mathematics at Cambridge University, England and has subsequently held various positions that have involved mathematics and computing. Initially John was involved in Sonar Systems research study theoretical and practical aspects of sound in dispersive mediums. Subsequently he worked for the Oil and Gas industry, both on the machinery and platform aspects. He then spent time in the Middle East working on refinery and equipment optimisation and planning.

He then became more involved with software development methods working on collaborative projects in Berlin, Germany and Paris, France before joining a company that developed S, the precursor to R. Subsequently he has remained very active in the R community supporting systems developments that include R (and other data modeling languages).

He is experienced in R, Python, C# as well as modern web development techniques.

Tracey Thomas

Tracey received her Masters in Information Science at the University of Florida. She is currently working with Projections Research Inc. in business development and management.